Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 9,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $56.36, for a total value of $507,240.00. Following the completion of the transaction, the director now owns 86,697 shares in the company, valued at approximately $4,886,242.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Lewis Clayton Jr. Cantley also recently made the following trade(s):
- On Wednesday, July 19th, Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.14, for a total value of $196,490.00.
- On Wednesday, June 14th, Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $50.87, for a total value of $101,740.00.
- On Thursday, May 25th, Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total value of $95,895.60.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 0.10% on Friday, hitting $57.17. The stock had a trading volume of 345,338 shares. The stock has a 50 day moving average price of $53.35 and a 200 day moving average price of $50.13. The company’s market cap is $2.76 billion. Agios Pharmaceuticals, Inc. has a 1-year low of $35.84 and a 1-year high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. During the same period in the previous year, the firm posted ($0.64) EPS. The business’s revenue for the quarter was down 66.4% compared to the same quarter last year. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post ($6.44) EPS for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. C WorldWide Group Holding A S bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth approximately $105,000. Bank of Montreal Can boosted its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth approximately $129,000. Russell Investments Group Ltd. boosted its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC boosted its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares in the last quarter. 83.83% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have issued reports on the company. Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 26th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Credit Suisse Group AG reiterated an “outperform” rating and issued a $61.00 price target on shares of Agios Pharmaceuticals in a report on Tuesday, April 18th. Finally, Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 18th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $62.88.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
